Clinical trials of MGI-114

ONCOLOGY

Volumn 13, Issue 2, 1999, Pages 233-237

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043223618     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. McMorris TC, Kelner MJ, Wang W, et al: Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties. J Natl Prod 59(9):896-899, 1996.
2. Woynarowski JM, Napier C, Koester SK, et al: Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 54:1181-1193, 1997.
3. Herzig MCS, Arnett B, MacDonald JR, et al: Uptake and macromolecular binding of 6-hydroxymethylacylfulvene (HMAF, MGI 114) in a leukemia cell line, CEM (abstract). Proc Am Assoc Cancer Res 39:66, 1998.
4. Kelner MJ, McMorris TC, Estes L, et al: Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 55(21):4936-4940, 1995.
5. MacDonald JR, Muscoplat CC, Dexter DL, et al: Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57(2):279-283, 1997.
6. th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. 1998.
7. Kelner MJ, McMorris TC, Estes LA, et al: Efficacy of MGI 114 in the myeloid leukemia HL60/MRI xenograft model (abstract). Proc Am Assoc Cancer Res 39:227, 1998.
8. th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998.
9. Kelner MJ, McMorris TC, Taetle R: HMAF (MGI 114) has antitumor activity in the mdrt/ gp170-positive human MV522 metastatic lung carcinoma xenograft (abstract). Proc Am Assoc Cancer Res 38:220, 1997.
10. th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998.
11. Marty J, MacDonald J, Mangold G, et al: Evidence of synergistic antitumor activity with MGI 114 in combination with irinotecan (ITN) or 5-fluorouracil (5-FU) against a human colon tumor xenograft model (abstract). Proc Am Assoc Cancer Res 39:527, 1998.
12. Barrera H, MacDonald J, Hilsenbeck S, et al: In vitro antitumor activity of MGI 114 in combination with topotecan, taxol, cisplatin, etoposide, or gemcitabine against pediatric tumor cell lines (abstract). Proc Am Assoc Cancer Res 39:527 (#3588), 1998.
13. Eckhardt SG, Baker SD, Weiss GR, et al: A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114. in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 17:233a, 1998.